Clinical trial

A Phase 1/2a Study of K-1728 in Advanced Solid Tumors

NCT07861932

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2026-10-01Date precision: month

Registry last updated2026-10-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Solid Tumorsunresolved

PIK3CA Gene Mutationunresolved

Interventions

K-1728DRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

PalbociclibDRUG · verified · RxNorm: palbociclib

Sponsors & collaborators

KymaThera, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07861932 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.